Media Release: Roche Pharmaceuticals.

(From MediaNet Press Release Wire)

MEDIA RELEASE PR19312 Tarceva Receives Positive Opinion in EU for the Treatment of Patients With Lung Cancer BASEL, Switzerland, June 27 /PRNewswire-AsiaNet/ -- Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive survival benefit that Tarceva offers patients with late stage lung cancer," said William M. Burns, CEO Division Roche Pharma. "This brings new hope to lung cancer patients who have currently very limited treatment options." Tarceva is the first and only EGFR-targeted treatment to have shown a significant survival benefit in patients …